Roche Softens TIGIT Blow With Poseida Buyout

The SKYSCRAPER-01 trial’s failure to generate an overall survival benefit is the biggest blow yet to the TIGIT inhibitor class, but Roche looking to move on with its buyout of the CAR-T therapy company.

Roche_Basel

Roche has sought to temper the long-expected news that its cancer immunotherapy, tiragolumab, has failed in a key Phase III study by announcing a $1.5bn buyout of the cell therapy company Poseida.

Topline results released on 26 November confirmed that the TIGIT inhibitor failed to improve overall survival in the SKYSCRAPER-01 trial...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Therapy Areas